VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASTRO 2022 | Future developments in cervical cancer treatment

Jyoti Mayadev • 21 Oct 2022
ASTRO 2022
Cervical Cancer Gynecological Cancer
CALLA Immuno-Oncology Radiotherapy

Jyoti Mayadev, MD, University of California San Diego Medical Center, San Diego, CA, highlights the need for improved treatments for high-risk cervical cancer patients, including developments in immunotherapy and chemoradiotherapy. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting with Astra Zeneca

More from Jyoti Mayadev

5:20
CALLA: Phase III study of durvalumab and chemoradiotherapy for cervical cancer
Jyoti Mayadev • 21 Oct 2022
1:42
Unmet needs in radiotherapy for cervical cancer
Jyoti Mayadev • 21 Oct 2022

Related Videos

2:55
Olaparib considerably increases PFS in ovarian cancer
Domenica Lorusso
7:39
Ovarian news from ESMO 2018: SOLO-1 results for olaparib
Kathleen Moore
1:10
Matching treatment to molecular profiles in endometrial cancer
Carien Creutzberg
0:55
Making endometrial cancer more receptive to treatment
Carien Creutzberg
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals